DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its first quarter 2024 financial results on May 8th, followed by a business update and live conference call on May 9th. The company focuses on developing recombinant KLK1 (DM199) for acute ischemic stroke treatment.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8^th. DiaMedica will host a live conference call on Thursday, May 9^th at 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:
Date:	Thursday, May 9, 2023
Time:	7:00 AM CT / 8:00 AM ET
Web access:	https://app.webinar.net/jDdlnVm9Ewq
Dial In:	(646) 357-8785
Conference ID:	07657

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 16, 2024, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 07657#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502797716/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com



Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

When will DiaMedica Therapeutics release its first quarter 2024 financial results?

DiaMedica Therapeutics will release its first quarter 2024 financial results after the markets close on May 8th.

What is the focus of DiaMedica Therapeutics in terms of drug development?

DiaMedica Therapeutics is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke.

When will DiaMedica Therapeutics host a live conference call for a business update?

DiaMedica Therapeutics will host a live conference call on May 9th at 7:00 AM Central Time to provide a business update and discuss financial results.

How can interested parties access the DiaMedica Therapeutics conference call?

Interested parties can access the DiaMedica Therapeutics conference call by dialing in or listening to the simultaneous webcast. Web access and dial-in details are provided in the press release.

What is the lead candidate of DiaMedica Therapeutics for acute ischemic stroke?

DiaMedica Therapeutics' lead candidate for acute ischemic stroke is DM199 (rinvecalinase alfa), the first pharmaceutically active recombinant form of the KLK1 protein.